Fulgent Genetics (NASDAQ:FLGT) (NASDAQ: FLGT) is a molecular diagnostics company specializing in high‐throughput genetic testing and data analytics. Leveraging next‐generation sequencing (NGS) technologies, proprietary bioinformatics pipelines and artificial intelligence, Fulgent provides comprehensive testing solutions across a broad spectrum of applications, including hereditary disease screening, oncology panels, reproductive health assays and pharmacogenomics. The company’s cloud‐based platform facilitates rapid sample processing, variant interpretation and customizable reporting for clinicians, researchers and public health agencies.
Since its founding in 2011, Fulgent has expanded its service offerings to include both pre‐designed and custom genomic panels. These services support disease risk assessment, treatment planning and drug development. In response to the COVID‐19 pandemic, Fulgent also deployed scalable infectious disease testing capabilities, establishing high‐capacity laboratories to aid in community screening and hospital safety protocols. This agility underscores Fulgent’s commitment to delivering timely, actionable insights when public health demands intensify.
Headquartered in Temple City, California, Fulgent maintains a network of CLIA‐certified and CAP‐accredited laboratories in the United States, complemented by partnerships in Asia and Europe. Under the leadership of Dr. Ming Hsieh, founder and Executive Chairman, and Brandon T. Holt, President and Chief Executive Officer, the company continues to innovate its genomics platform to address evolving clinical and research needs. Fulgent’s end‐to‐end capabilities—from sample accessioning through variant classification—are designed to ensure high analytical sensitivity and specificity.
Fulgent serves a diverse customer base, including physicians, genetic counselors, academic institutions, pharmaceutical companies and government entities. By integrating advanced sequencing workflows with streamlined logistics and digital reporting, the company aims to accelerate the adoption of precision medicine and support more informed healthcare decisions globally. Ongoing investments in automation, data security and laboratory infrastructure position Fulgent to scale its offerings while maintaining stringent quality standards.
